Exploration of Side Effects and Patient-Reported Outcomes in First Line Compared to Late Line Chemotherapy and Targeted Therapies
Journal of Thoracic Oncology(2023)
Abstract
With the advent of new therapies and more clinical trials, it is not uncommon for people with lung cancer to transition through multiple lines of therapy. However, how individuals feel and function during different treatment classes as well as first-line (1L) treatment compared to later treatments is poorly documented. This is due to limited real-world patient experience data linked with clinical data. Yet, patient experience data is a powerful tool in understanding the impacts of treatments and how these affect a person's quality of life (QoL).
MoreTranslated text
Key words
Real-world,data,Patient-reported outcomes,Financial difficulties
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined